RxDoctor Payments Data

Robert Bransfield

Psychiatry · Red Bank, NJNPI 1467449769

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $334,086 of the $414,751 with a category attached, or 80.6%. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 90.6% of it on its own, with 37 other manufacturers making up the rest. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$414,751in general payments, 2019–2025

Across 1,203 payments — averaging $344.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$376K
  • Supernus Pharmaceuticals, Inc.$17K
  • Idorsia Pharmaceuticals US Inc$8K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Sunovion Pharmaceuticals Inc.$2K
  • AbbVie$2K
  • plus $8K from 32 others

What the payments were for

  • Consulting fees$12,0003%
  • Speaking & faculty fees$334,08681%
  • Travel & lodging$44,71411%
  • Food & beverage$23,6396%
  • Education$3120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414,751 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate22$379,890
CaplytaLumateperone Tosylate63$101,077
VraylarCariprazine Hcl58$83,955
ProvigilModafinil12$53,778
EmsamSelegiline25$49,855
LamictalLamotrigine48$49,300
Wellbutrin XlBupropion Hcl12$22,612
SunosiSolriamfetol Hcl11$18,678
ViibrydVilazodone Hcl48$16,095
RexultiBrexpiprazole12$15,744
AnafranilClomipramine Hcl13$12,780
CymbaltaDuloxetine Hcl11$12,003
VyvanseLisdexamfetamine Dimesylate27$9,931
Lurasidone Hcl77$7,664
FetzimaLevomilnacipran Hcl15$7,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Viibryd, Fetzima$1,512$107,325121 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$375,691$101,07763 claims
Axsome Therapeutics, Inc.Sunosi$302$18,67811 claims
Otsuka America Pharmaceutical, Inc.Rexulti$588$15,74412 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$790$9,93127 claims
Tris Pharma IncDyanavel Xr$338$4,79211 claims
Corium, LLCAzstarys$284$4,48211 claims
Almatica Pharma LLCSertraline Hcl$259$1,450283 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Red Bank

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →